Clinical Trial Update: Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting safety and efficacy results for pertuzumab in castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Perjeta (pertuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-06-23